Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

Impact · against what's priced in

Artelo Biosciences' positive preclinical data for ART26.12 in spinal cord injury models expands the potential addressable market for its lead candidate. While preclinical results are lower-signal than clinical trials, the data supports the broad therapeutic potential of the FABP5 inhibitor in high-unmet-need chronic pain areas.

ARTL+0.40

No priced-in read yet